Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
31.75
Industry P/E
--
Debt to Equity
-0.23
ROE
-11.91 %
ROCE
8423.53 %
Div. Yield
0 %
Book Value
--
EPS
-15.75
CFO
$-277.00 Mln
EBITDA
$-361.02 Mln
Net Profit
$-384.84 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Mustang Bio (MBIO)
| -86.89 | -12.78 | -72.58 | -92.66 | -87.34 | -78.00 | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Mustang Bio (MBIO)
| -86.67 | -77.21 | -76.20 | -56.14 | -7.23 | 38.78 | -75.29 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.66 | 10,315.11 | 21.27 | 23.13 | |
| 303.59 | 8,705.27 | 22.77 | 66.44 | |
| 27.70 | 10,589.59 | -- | -28.77 | |
| 108.32 | 10,559.67 | 32.44 | 14.16 |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy... for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts. Address: 95 Sawyer Road, Waltham, MA, United States, 02453 Read more
Executive Chairman
Mr. Michael S. Weiss Esq.
Executive Chairman
Mr. Michael S. Weiss Esq.
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Mustang Bio Inc (MBIO) stood at $ 9 Mln as on 31-Dec-24
The share price of Mustang Bio Inc (MBIO) is $1.16 (NASDAQ) as of 29-Apr-2025 12:40 EDT. Mustang Bio Inc (MBIO) has given a return of -87.34% in the last 3 years.
Mustang Bio Inc (MBIO) has a market capitalisation of $ 4 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Mustang Bio Inc (MBIO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mustang Bio Inc (MBIO) and enter the required number of quantities and click on buy to purchase the shares of Mustang Bio Inc (MBIO).
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts. Address: 95 Sawyer Road, Waltham, MA, United States, 02453
The CEO & director of Mr. Michael S. Weiss Esq.. is Mustang Bio Inc (MBIO), and CFO & Sr. VP is Mr. Michael S. Weiss Esq..
There is no promoter pledging in Mustang Bio Inc (MBIO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Mustang Bio Inc. (MBIO) | Ratios |
|---|---|
|
Return on equity(%)
|
840.11
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Mustang Bio Inc (MBIO) was $0 Mln.
